Uncategorized

A person may have more than one sexual partner at a time if they have several sexual partners. Alternatively, it may imply having several lovers at once. According to a 2018 research, having numerous sexual partners is defined as “having more than one sexual partner throughout time.”

This could entail switching between different sexual partners. It might also refer to having several sexual partners at the same time. The typical number of sexual partners that people have is examined in this article. It also looks at the potential advantages and drawbacks of having many partners.

How many sexual partners does the typical person have?

Family Growth National Survey

Statistics from 2015 to 2019 are available from the Centers for Disease Control and Prevention (CDC) in the United States on persons who have engaged in vaginal, oral, or anal intercourse with a partner of a different sex. According to the data, the median number of sexual partners for men and women was 6.3 and 4.3 respectively.
An online poll for 2021
A study by Trusted Source of 1,987 persons between the ages of 18 and 70 examined sexual behaviour trends across a range of ages, ethnicities, sexual orientations, and socioeconomic statuses.

The average number of lifetime sexual partners among all participants was:

• For oral sex, 8.5
• 11.4 for genitalia
• For anal sex, 2.1

Researchers observed that:

• 2.4% of participants claimed to have engaged in oral intercourse with more than 50 people.
• 3.9% claimed to have engaged in more than 50 vaginal sex relationships.
• 3.6% claimed to have engaged in anal intercourse with more than 15 people.

After reaching a peak for males at age 60 and females at age 40, the number of sexual partners throughout a lifetime began to fall.

Is having several sexual partners acceptable?

Having several sexual partners is OK. Sexual health is defined by the World Health Organization (WHO) as: a state of well-being physically, emotionally, mentally, and socially with regard to sexuality; a positive, respectful approach to sexual relationships and sexuality; the possibility of having safe, pleasurable sexual experiences; and the respect, protection, and realisation of the sexual rights of all parties involved.

According to the American Sexual Health Association (ASHA), there is no right or wrong way to experience sexual pleasure as long as there is consent and no risk to anybody involved. This may entail engaging in several sexual relationships.  According to ASHA, recognising one’s own sexual needs and responsibilities as well as acknowledging those of one’s partner or partners are key components of a fulfilling sexual life.

Benefits:

According to studies from 2021, having sex may have the following advantages:

Improved sleep: According to research by 2019Trusted Source, orgasms aid in the promotion of sleep. The impression of better sleep outcomes was associated with orgasms with a partner, while higher sleep quality was associated with orgasms during masturbation.

Improved immune function: An earlier study from 2004 discovered that those who engaged in sexual activity once or twice a week had higher levels of IgA, a pathogen-fighting antibody.

Release of oxytocin: This hormone has a beneficial effect on how people cope with stress, anxiety, and bad situations.

Improved physical health: Sexual activity is a form of physical activity, which is good for the heart and the brain. A 2013Trusted Source study discovered that sexual activity of a moderate intensity can be considered a substantial kind of exercise.

Improved longevity for men: According to research, men’s sexual activity, interest in sex, and the quality of their sex life are all associated in a favourable way with a higher life expectancy. Additionally, sexual engagement was linked to a decreased chance of dying from cancer and other diseases.

Sexual interactions may also have a favourable impact on general happiness and life satisfaction. Increased mortality rates and self-reported rates of poor health may be linked to lower levels of sexual engagement.

Having several partners could:

• provide, sexual fulfillment, variety, and pleasure
• enhance endorphin production, which aids in the fight against infections and cancer cells
• reduce low levels of potential sexual interest

Risks:

The English Longitudinal Study of Aging discovered that having more sexual partners might raise your chance of getting STIs (STIs). These can then result in health hazards, even as people age.

In comparison to having one sexual partner or none, the researchers discovered that having 10 or more lifetime partners raised the probability of receiving a cancer diagnosis.

For instance, hepatitis B and C can raise the chance of getting liver cancer. Additionally, the human papillomavirus, or HPV, can raise the chance of developing:

• cervical cancer
• mouth cancer
• anal cancer
• penile cancer
• prostate cancer

Males who had more than 20 female sexual partners, however, had a lower risk of prostate cancer, according to an older study from 2014.

The study also discovered that men who have had more than 20 male partners may be at a higher risk for prostate cancer.

The risk of HIV transmission might also rise with many partners.

Psychological impact:

In a 2018 study, the relationship between depression, drug usage, and the quantity of sex partners was examined.

199 Northern and Indigenous ladies from the Canadian Northwest Territories, aged 13 to 17, were involved in the research.

The study did not discover a connection between depression and the number of sex partners people had. Drug usage had an impact on a person’s number of sex partners after having a direct impact on depression and substance use.

A previous study from 2013Trusted Source showed no correlation between anxiety or depression and having numerous relationships, although it did find a link between drug usage and having multiple partners.

The benefits of sexual activity may include improved moods, less stress, and better sleep.

Physical impact:

According to research, more frequent sex reduces the chance of deadly heart conditions, prostate cancer, and breast cancer.

The frequency and quality of sex exhibited protective benefits against cardiovascular issues in later life among the 1,158 female and 1,046 male participants, who were 57-85 years old and resided in the U.S.

Researchers have connected the endorphins released during sexual engagement to an increase in the activity of natural killer cells. This action include assisting in the battle against viruses and cancer cells.

Based on a 2018 research, the timing of partnerships may be related to a higher risk of getting a STI.

People may be more likely to get STIs or spread these diseases if they have several sexual partners in a particular time frame.

The study discovered that when there was a pause between sexual partners, the risk of receiving a STI diagnosis was significantly reduced. A separation of four months or more for females and six months or longer for males decreased the likelihood of receiving a STI diagnosis.

A increased risk of HIV exposure or transmission may also exist for those who engage in many sex relationships.

Emotional impact:

In the 2017 British National Survey of Sexual Attitudes and Lifestyles, 6,669 females and 4,839 men aged 16 to 74 years old were asked about the causes of their lack of interest in sex. The individuals disclosed having at least one sexual partner in the previous year, whether they were of the same sex or not.

According to the study, women who had three or more sexual partners in the previous year were less likely to report having little interest in sex than women who had only one partner during that time.

No correlation between having many sexual partners and having little interest in men was discovered by the poll.

Sex with numerous partners may feel impersonal to some individuals, and this might have a bad emotional effect. The emotional toll of ending short-term relationships is also possible.

Precautions:

Some methods for having numerous sexual partners without risky behaviour include:

• using a condom or a dental dam every time
• having regular STI testing
• using condoms on sex toys, and washing toys before and after each use
• avoiding excess alcohol and drug use, as this can increase risk-taking

According to ASHA, a person who engages in sexual non-monogamy and consistently and correctly employs barrier measures is less likely to develop a STI than a person who engages in mutual, serial monogamy, doesn’t use barrier methods, or has a partner who is STI-unknown.

Summary

If a person has intercourse with one person, then another afterwards, they have numerous sexual partners. If a person has more than one sexual partner at the same time, they also have numerous partners. Having several sexual partners is acceptable as long as everyone gives their consent and is not put in danger. Having more than one spouse can have both advantages and disadvantages. Use barrier measures and undergo frequent STI testing to engage in safe sex.

Oak and ragweed pollens are two of the most prevalent allergens in the contiguous United States. Models were developed by scientists at the Rutgers Environmental and Occupational Health Sciences Institute to predict how these two pollen distribution patterns would vary due to climate change. Reading the findings, which were published in the journal Frontiers in Allergy, can make your eyes wet.

According to a study lead by Panos Georgopoulos, professor of Environmental and Occupational Health and Justice at the Rutgers School of Public Health, airborne pollen loads would considerably rise as a result of climate change by 2050. Where pollen has historically been limited, some of the highest increases will take place.

“Pollen is an excellent sentinel for the impacts of climate change because shifts in variables like carbon dioxide and temperature affect the way plants behave,” said Georgopoulos, who also is director of the Computational Chemodynamics Laboratory at Rutgers and faculty at Robert Wood Johnson Medical School. “At the same time, the production of pollen and pollen’s influence on allergic disease has been increasing due to climate change, and this is one of few studies to forecast this trend into the future.”

Lack of information has hindered earlier attempts to link pollen indices with climate change. For instance, there are roughly 80 pollen collection stations in the United States that are run by a range of public and commercial organisations and employ various sample techniques.

The U.S. Environmental Protection Agency (EPA) manages the Community Multiscale Air Quality modelling system, an open-source programme, which the researchers modified to forecast the distributions of allergenic oak and ragweed pollen under past (2004) and future (2047) circumstances.

The findings indicated that even under conditions of mild warming, the pollen season will begin earlier and remain longer across the United States, with rising average pollen concentrations across the majority of the country.

In the Northeast and Southwest, mean ragweed pollen concentrations might increase by more than 20%, while mean oak pollen concentrations could rise by more than 40%. Shifts in regional pollen were also noted. By the middle of the century, oak pollen levels might quadruple in regions of Nevada and northern Texas, while ragweed pollen levels in Massachusetts and Virginia could rise by 80% by 2050.

The Rutgers Ozone Research Center is now working on a project to examine how climate change may affect the state’s air quality. The initiative is financed by the EPA and New Jersey. The bulk of that work examines the state’s struggles with ground-level ozone, a byproduct of fossil fuel combustion that can damage the lungs.

“New Jersey’s air quality is going to be adversely impacted by climate change, both in terms of anthropogenic pollution and increased levels of pollen,” Georgopoulos said. “For people with asthma, exposure to pollen and irritants like ozone increases the odds of respiratory illness. To protect the most vulnerable, we need to understand how these irritants will behave in a warming world.”

The excruciating joint pain that can result from infection with the recently discovered Chikungunya virus can last for months or even years. Researchers from Oregon Health & Science University and its partners are striving to develop what may be the first ever medicine for this condition.

Although scientists have worked to create vaccines and drugs to fight the virus, none have been approved as of yet. The latest study might lead to the molecule going through its first human testing by the end of 2027.

“We have the potential to develop an antiviral that could be used to treat millions of people during large Chikungunya outbreaks, and prevent long-term disease in people who are persistently affected by this debilitating disease,” said Streblow, a professor at OHSU’s Vaccine and Gene Therapy Institute.

Together with Richard Whitley, M.D., of the University of Alabama in Birmingham, and Mark T. Heise, PhD, of the University of North Carolina at Chapel Hill, Streblow is in charge of the new research effort.

Researchers from the University of Colorado Denver, Southern Research in Alabama, and SRI Biosciences in California are also a part of the team. Warmer temperatures are home to the mosquito species that carry the virus through their bites. Since its discovery in Africa in 1952, the chikungunya virus has spread to Asia, the Indian subcontinent, the Americas, and Europe. Its geographic range could be widened by climate change. 77 fatalities and more than 360,000 cases of Chikungunya have been reported worldwide so far this year, with the majority of cases happening in Brazil, India, and Guatemala.

The virus started to spread in the US in 2014, but it did so slowly. According to the US Centers for Disease Control and Prevention, since then there have been 13 locally acquired cases in US states. For one to two weeks after the first infection, Chikungunya can produce fever, joint and muscular discomfort, a rash, and other symptoms. A increased risk of serious illness or death exists among young children, elderly individuals, those with high blood pressure, and people who have diabetes. While the majority of patients recover completely, 30 to 40% of them will continue to have chronic Chikungunya arthritis, which causes persistent joint pain for months or even years. Some people are unable to work as a result of the agony it causes.

The investigational Chikungunya antiviral medicine is intended to lower the overall viral load, much as the COVID treatment Paxlovid. The substance, which is still under patent protection, is known as a 2-pyrimidone small molecule inhibitor. It functions by attaching to the viral RNA polymerase, which is used by viruses to multiply. Because it specifically targets a specific location on viral RNA polymerase and has never been used to treat people, Streblow refers to the drug as “first in class.”

When administered one to two weeks after infection, the investigational antiviral was found to lower Chikungunya virus levels by up to 1,000 times and stop long-term joint problems in earlier, unpublished study with mice. The study team also discovered that persistent viral loads, which are regarded to be the root of chronic illness, were decreased when the chemical was administered later.

The research team is currently attempting to modify the chemistry of the antiviral chemical and create a pill that can be swallowed. The group intends to use more sophisticated animal models to examine the efficacy and safety of the reformulated substance.

The study team’s next goal is to apply for an investigational new drug with the American Food and Drug Administration. If their proposal is accepted, OHSU would direct a Phase 1 clinical trial to examine the safety and effectiveness of the novel therapy in human subjects.

Patients receiving efgartigimod, a drug being studied for the treatment of chronic primary immune thrombocytopenia (ITP), had a much greater increase in platelet counts, which are essential for clotting and stopping bleeding, in contrast to those receiving a placebo.

The Georgetown University Medical Center participated in the worldwide ADVANCE IV clinical study. Immunoglobulin G (IgG), a form of autoantibody (antibodies directed against a person’s own proteins), is present in individuals with ITP and accelerates platelet clearance from the circulation while simultaneously having the potential to decrease platelet synthesis. Particularly in individuals who have not reacted well to prior ITP medications, ITP can be exceedingly challenging to treat.

Catherine Broome, M.D., associate professor of medicine at Georgetown and lead researcher in the global ADVANCE IV project, presented the study results in a plenary session of the American Society of Hematology annual meeting in New Orleans on December 11, 2022.

“The results of the ADVANCE IV study provide an important answer regarding the potential benefits of efgartigimod as a treatment for ITP. There remains significant unmet need in treating ITP,” says Broome. “ITP is also associated with debilitating fatigue and can have significant impacts on mental health, including anxiety, fear and depression, which is why it’s been so essential to find additional therapies to treat the disease.”

According to estimates, there are around 3.3 new instances of ITP identified each year in the United States for every 100,000 persons in the general population. Females are more likely to develop ITP between puberty and 60 years of age.
The mechanism of action of efgartigimod is unique. While having no effect on crucial immune system elements including lymphocytes, IgG synthesis, or the body’s innate immune system, it reduces IgG levels.

131 individuals were enrolled in the phase III, double-blinded ADVANCE IV clinical study from North America, Europe, and Japan. For a total of 24 weeks, the subjects were randomised to receive either efgartigimod or a placebo. Prior to being randomly allocated to the experiment, every patient had low platelet counts and underwent at least one ITP therapy; two-thirds of the participants had gone through three or more ITP treatments.

The company that created the drug efgartigimod, argenx, funded the study. The medication, marketed under the trade name Vyvgart, has only been licenced for use in treating a specific kind of myasthenia gravis, a disorder characterised by impaired nerve and muscle communication brought on by autoantibodies.

In the ADVANCE IV trial, chronic ITP patients who received efgartigimod as opposed to a placebo showed a significant improvement in sustained platelet response (21.8% vs. 5%, respectively) during at least four of the last six scheduled trial visits, with about 50% of those who responded to the medication experiencing doubled platelet counts. Regardless of age, illness severity, time since diagnosis, previous ITP therapy, or usage of other drugs, response to the drug was shown in all types of patients. The drug’s negative effects that were most often reported were bruises, headaches, blood in the urine, and rash-like signs on the skin caused by bleeding. There were no documented severe treatment-related adverse effects.

“Our hope is that as more therapies are available to patients with ITP, fewer patients will experience bleeding events and fatigue, leading to an overall increase in their quality of life,” says Broome.

In this trial, the medication was given intravenously. Subcutaneous administration of the medicine is being tested concurrently to determine if it is equivalent to intravenous administration in terms of effectiveness. The second part of 2023 is when the subcutaneous trial is anticipated to provide results.

“Our next step is already underway,” says Broome, who treats patients at MedStar Georgetown University Hospital. “ADVANCE-plus is an open-label extension of this trial, that will provide data regarding long term effectiveness and safety of efgartigimod by observing participants for up to 60 weeks compared to the 24 weeks we’re reporting on now.”

A recent research found that the novel medication modakafusp alf offers early promise in treating the bone marrow malignancy multiple myeloma. At the 2022 American Society of Hematology (ASH) Annual Meeting, researchers from the University of Pennsylvania’s Abramson Cancer Center reported their result (Abstract 565). 43 percent of patients who received 1.5 mg of modakafusp every four weeks as part of a Phase I/II multicenter study (NCT03215030) saw a partial response or a more than 50% decline in their malignancy. Participants in the trial had at least three prior lines of therapy, and after the preceding therapy, their illness had relapsed or stopped responding.

“We are excited by these findings and continue to be optimistic about the potential this treatment holds for patients with multiple myeloma,” said presenting author Dan Vogl, MD, an expert in blood cancers, medical director of the Clinical Research Unit at Penn Medicine’s Abramson Cancer Center, and an associate professor of Hematology-Oncology at the Perelman School of Medicine of the University of Pennsylvania. “We have been working with this new medication at Penn since we gave it to the first patient ever to receive it five years ago. We now see that a substantial number of patients benefit from modakafusp as a single agent, including patients whose myeloma has become resistant to other treatments, which is really impressive.”

A fusion protein called modakafusp (created by Takeda Pharmaceuticals) directs interferon, a pro-inflammatory hormone also used to treat various malignancies and viral infections, to cells that express CD38, a surface marker seen on myeloma cells and a number of immune cells.

In the United States, there are anticipated to be 12,640 fatalities from multiple myeloma in 2022, according to the American Cancer Society. Less than 1% of the population gets the cancer, making it rare. Despite medical advancements, myeloma is presently incurable, and all patients experience malignant relapses following first chemotherapy and other initial lines of therapy.

In this study, modakafusp showed promise in patients for whom other treatments targeting the same target, such as well-known monoclonal antibodies like daratumumab and isatuximab, had lost their efficacy. The study’s preliminary findings were presented at the ASH Annual Meeting in 2021. The medicine has tolerable side effects and induces potent anti-myeloma responses, according to the final safety and effectiveness studies released this year.

“Modakafusp has a truly novel mechanism of action, delivering a hormonal signal directly to target cells that simultaneously is toxic to cancer cells while stimulating an immune response. We saw responses in patients whose cancer did not respond to or who experienced a relapse after receiving the anti-CD38 antibody drugs that are currently on the market,” Vogl said. “We also saw responses in patients whose myeloma had developed resistance to all currently available effective therapies.”

As would be expected in a group that has had so many previous treatments, the majority of research participants (87%) had adverse events linked to their treatment. Neutropenia, or a reduction in white blood cells, and thrombocytopenia, or a low blood platelet count, were the most frequent adverse effects among research participants; around one-third of patients experienced moderate responses after receiving the medicine by infusion.

In order to determine the ideal dose of modakafusp and learn more about its efficacy in treating myeloma, Vogl and his colleagues are currently recruiting patients in a randomised phase II research.

A three-drug regimen that produced remarkable remissions in chronic lymphocytic leukaemia (CLL) patients in a clinical research is extremely helpful in patients with high-risk variations of the illness, according to a new phase 2 clinical trial run by clinicians at the Dana-Farber Cancer Institute.

Acalabrutinib, venetoclax, and obinutuzumab were reported to elicit profound remissions in 89% of participants in the initial cohort of the trial, which included patients with any subtype of CLL. The second cohort discovered a same 83% deep-remission rate, although it only included individuals with high-risk CLL. Dr. Christine Ryan, the study’s principal investigator from Dana-Farber, will present the research’s findings at the ASH Annual Meeting.

68 patients with previously untreated CLL are enrolled in the trial, which is being conducted at Dana-Farber, Beth Israel Deaconess Medical Center, Stamford (Conn.) Hospital, and Lifespan Health System in Rhode Island. Of these, 41 have a mutation and/or deletion in the TP53 gene in their tumour cells, an abnormality linked to an aggressive form of the disease.
Acalabrutinib, an antibody treatment, obinutuzumab, and venetoclax are administered to patients according to a predetermined regimen that may last up to 16 cycles.

83% of the high-risk patients had undetected minimum residual disease (MRD), or no detectable CLL cells per 100,000 white blood cells, in their bone marrow after a median follow-up of 35 months.

Moreover, 45% of patients experienced the most profoundly discernible response to the therapy: total remission and undetectable MRD in the bone marrow.
Researchers discovered that the therapy was generally well-tolerated, with minimal incidence of infections and cardiovascular issues.

Ninety-three percent of the study participants were still alive and their diseases had not progressed after almost three years of follow-up. The study has helped to establish a major phase III trial of the regimen for CLL patients without a high-risk condition, which may result in FDA approval of the regimen.

“Our data provide foundational support for using this triplet therapy in patients with high-risk CLL patients,” says study senior author and principal investigator Matthew Davids, MD, MMSC, of Dana-Farber.

Modakafusp alfa, a novel medicine, has shown early promise in treating multiple myeloma, a kind of bone marrow cancer, according to findings presented at the 2022 American Society of Hematology (ASH) Annual Meeting by scientists from the University of Pennsylvania’s Abramson Cancer Center.
Patients who received 1.5 milligrammes of modakafusp every four weeks as part of the Phase I/II multicenter study (NCT03215030) had a partial response, or a 50% decline in their malignancy. Patients in the study had had at least three rounds of prior therapy, and their condition had either relapsed or stopped responding to the earlier drug.

“We are excited by these findings and continue to be optimistic about the potential this treatment holds for patients with multiple myeloma,” said presenting author Dan Vogl, MD, an expert in blood cancers, medical director of the Clinical Research Unit at Penn Medicine’s Abramson Cancer Center, and an associate professor of Hematology-Oncology at the Perelman School of Medicine of the University of Pennsylvania. “We have been working with this new medication at Penn since we gave it to the first patient ever to receive it five years ago. We now see that a substantial number of patients benefit from modakafusp as a single agent, including patients whose myeloma has become resistant to other treatments, which is really impressive.”

A fusion protein called modakafusp (created by Takeda Pharmaceuticals) directs interferon, a pro-inflammatory hormone also used to treat viral infections and other malignancies, to cells that carry CD38 on their surface. CD38 is a marker found on myeloma cells as well as a number of immune cells.
In the United States, there are anticipated to be 12,640 fatalities from multiple myeloma in 2022, according to the American Cancer Society. Less than 1% of the population gets the cancer, making it rare.

Despite medical advancements, myeloma is presently incurable, and all patients experience malignant relapses following first chemotherapy and other initial lines of therapy. In this study, modakafusp showed promise in patients for whom other treatments targeting the same target, such as well-known monoclonal antibodies like daratumumab and isatuximab, had lost their efficacy. The study’s preliminary findings were presented at the ASH Annual Meeting in 2021. The medicine has tolerable side effects and induces potent anti-myeloma responses, according to the final safety and effectiveness studies released this year.

“Modakafusp has a truly novel mechanism of action, delivering a hormonal signal directly to target cells that simultaneously is toxic to cancer cells while stimulating an immune response. We saw responses in patients whose cancer did not respond to or who experienced a relapse after receiving the anti-CD38 antibody drugs that are currently on the market,” Vogl said. “We also saw responses in patients whose myeloma had developed resistance to all currently available effective therapies.”

According to expectations for this substantially pre-treated group, the majority of trial participants (87%) had adverse events due to the therapy. Neutropenia, or a reduction in white blood cells, and thrombocytopenia, or a low blood platelet count, were the most frequent side effects among research participants. About one-third of patients also experienced minor side effects following the medication’s infusion. In order to determine the ideal dose of modakafusp and learn more about its efficacy in treating myeloma, Vogl and his colleagues are currently recruiting patients in a randomised phase II research.

In two clinical investigations, researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai discovered that a new therapy that triggers the immune system to destroy bone marrow cancer cells was successful in as many as 73% of patients.

The medication, known as a “bispecific antibody,” attaches to both T cells and multiple myeloma cells and gives the T cells instructions to kill multiple myeloma cells. T cells are white blood cells that may be utilised to fight off infections. The researchers defined this strategy as “bringing your forces directly to the opponent.”

Even individuals whose malignancy was unresponsive to any of the licenced treatments for multiple myeloma were able to experience the benefits of the over-the-counter immunotherapy known as talquetamab. Unlike other authorised medicines, it targets the GPRC5D receptor, which is present on the surface of cancer cells.

Trials in phases 1 and 2 tested talquetamab. Two suggested dosages were determined by the phase 1 study, which was published in The New England Journal of Medicine (NEJM), and were put to the test in the phase 2 experiment. On Saturday, December 10, the findings of the Phase 2 study were presented at the annual conference of the American Society of Hematology.

Talquetamab may provide fresh hope for individuals with difficult-to-treat multiple myeloma because all research participants had previously undergone at least three different medications without experiencing a long-lasting remission.

“This means that almost three-quarters of these patients are looking at a new lease on life,” said Ajai Chari, MD, Director of Clinical Research in the Multiple Myeloma Program at The Tisch Cancer Institute and lead author of both studies. “Talquetamab induced a substantial response among patients with heavily pretreated, relapsed, or refractory multiple myeloma, the second-most-common blood cancer. It is the first bispecific agent targeting the protein GPRC5d in multiple myeloma patients.”

The majority of myeloma patients who receive conventional therapy frequently relapse. Additional medications are urgently required for patients who relapse or develop resistance to all current multiple myeloma therapy due to their dismal prognosis. Although it is an early-phase trial intended to assess tolerability and determine a safe dosage, this study is a crucial step towards addressing that need.
Between January 2018 and November 2021, 232 participants from various cancer sites across the world were enrolled in this Phase 1 clinical research.

Future trials will concentrate on dosages solely provided under the skin either weekly or every other week. Patients received a range of doses of the treatment either intravenously or injected under their skin.

The phase 2 trial presented at ASH corroborated the effectiveness and safety findings of the phase 1 investigation. In the phase 2 experiment, 145 individuals received a higher biweekly dosage whereas 143 patients received a weekly dose.
According to Dr. Chari, the combined response rate for these two groups was almost 73%. Except for individuals with a rare type of multiple myeloma that also affects organs and soft tissues, the response rate was maintained across all categories investigated.

Nearly 60% of patients in both groups had a “very excellent partial response” or better, and more than 30% had a full response (no detection of myeloma-specific markers) or better (indicating the cancer was substantially reduced but not necessarily down to zero).

In all dosage groups, the median response length to date was 9.3 months with weekly dosing, while the median time to a meaningful response was around 1.2 months. The length of response in the group receiving 0.8 mg/kg every other week as well as for patients in both dose groups who had a full response or better are still being studied. The majority of the time, side effects were minor and reasonably common.

The cytokine release syndrome, a cluster of symptoms including fever that is typical of immunotherapies, was seen by about three-quarters of patients. About half reported taste changes, approximately 60 percent reported skin-related adverse effects including redness, and about 50 percent reported nail problems. Very few patients (5–6%), according to the researchers, discontinued talquetamab medication due to adverse effects.

Talquetamab may be a viable option for patients whose myeloma has not responded to the majority of currently accessible therapies, giving them a chance to prolong their lives and take advantage of other novel and developing therapies as they are developed, according to Dr. Chari, who noted that the response rate observed in the study is higher than that for most currently accessible therapies. Janssen sponsored and provided funding for these studies.

Sex may be ingrained in our popular culture, but in Indian homes, talking about it still carries a stigma and a sense of shame. Because of this, the majority of people who have sexual health problems or are looking for information on sex frequently turn to shady web sites or heed the unreliable counsel of their friends. Let’s Talk Sex is a weekly sex column that appears on News18.com in an effort to combat the pervasive misunderstanding about sex. Through this column, we want to start sexual health discussions and address relevant concerns with subtlety and scientific understanding.

Period sex is definitely a term you’ve heard of, but you might not know exactly what it implies. Period sex is just having sex when you are having your period. And certainly, if both couples are at ease with it, it may be safe.

There is no proof, according to science, that having sex when you’re menstruating is bad for your health. Some people discover that having sex when they are menstruating provides advantages, such as easing period discomfort. Some people prefer their period to other times of the month for sex. Finally, before participating in sexual activity, keep in mind that some people discover that they are more sensitive to discomfort during their periods.

If you choose to get it on when you are on your period, there are a few things to bear in mind. The possibility of blood containing germs should also be taken into account, increasing the risk of infection during period sex. Utilizing defence can lessen such danger.

The advantages of having sex when menstruating

Having sex when you are menstruating has several advantages. First of all, since your progesterone and oestrogen levels are lower and your vagina is less sensitive to discomfort, it could be more enjoyable. This implies that it can take longer for you to have orgasm. During their periods, some women also experience increased libido and heightened desire.

Additionally, sex can help relieve PMS symptoms including cramping, bloating, and acne.

• Period cramp relief: Your uterus contracts during a period cramp. When you have your period, you notice blood as the lining is removed thanks to the contractions. Some women may find relief from menstrual cramps via orgasms, which stimulate the uterine muscles to spasm before relaxing and releasing the stress.

• Headache Relief: Hormonal changes throughout the menstrual cycle are a typical cause of headaches. Feel-good endorphins are also released during sexual activity, and they may be used to block off period pain and discomfort.

• Lubrication: If your vagina is dry, menstrual flow can function as a natural lubricant. This might increase sex comfort and lessen the need for lubricants from the shop.

THE RISKS RELATED TO PERIOD SEX

There are a few hazards involved with period sex, but they are not particularly concerning.

• Enhanced Risk of Infection: Because your uterine lining is already weakened, you are more prone to infection during your period because period blood might carry germs. As a result, if you don’t take great care to keep everything clean, you can get an infection.
• Pregnancy Concern: Another risk is that depending on where you are in your cycle, your chances of getting pregnant might change. While getting pregnant may be less likely if you have intercourse during your period, it is still possible. Some people’s shorter or irregular menstrual cycles have an impact on when ovulation, or the release of an egg.

Additionally, sperm may survive for up to five days in the reproductive system. This indicates that fertilisation can take place following intercourse. Use contraception anytime you have sex if you are not attempting to conceive, even if you are menstruation.

• Sexually Transmitted Infections: STIs are a significant risk of having sex, but period sex can increase their likelihood. Sexual contact between those who have HIV or hepatitis and those who are menstruation puts their partners at risk of contracting the infections since blood may spread these diseases. A person may be more susceptible to infections during their period due to changes in the vagina.

Your chance of acquiring other STIs, such as herpes, increases if you engage in unprotected intercourse during your period or at any other time. Use condoms if you have period sex to prevent contracting or passing along a STI.

• Tampons: If you used one during your period, remove it before engaging in sexual activity. A neglected tampon may be pushed further into the vagina during intercourse and result in an infection.

If a tampon becomes stuck in the vaginal canal deeply, a provider may need to remove it. You should seek emergency medical treatment if you are unable to remove the tampon on your own.

CAREFUL STEPS TO TAKE PRIOR TO PERIOD SEX
There are a few things you should take to ensure your safety and comfort if you and your partner decide to have sex when you are on your period.

• First things first: it’s better to postpone having sex until any open wounds or sores on your body have healed. You absolutely do not want your spouse to develop an illness.

• Secondly, you may always lay down a dark-colored towel on the bed or wherever you intend to get it on if either of you is worried about the mess. You may avoid worrying about stains in this manner.

• Last but not least, be sure to utilise a birth control method. It’s better to be cautious than sorry since just because you’re not ovulating doesn’t mean you can’t become pregnant.

IS SEX SAFE DURING MENSTRUATION, THEN?

It depends, is the response. If you choose to have sex while on your period, there are a few things to keep in mind. The first step in preventing STIs is to confirm that you are wearing a condom. Second, be conscious of the possibility of becoming pregnant while having your period. Last but not least, be aware that you can be more susceptible to STDs during your period. Period sex may be a wonderful, freeing experience if you’re okay with everything else. Just remember to keep your companion informed and go slowly. Enjoy!

According to a three-month pilot research of people with hypertension published by Elsevier in the Canadian Journal of Cardiology, yoga is more advantageous than stretching activities for enhancing cardiovascular health and wellness. Yoga lowered resting heart rate and systolic blood pressure, which decreased 10-year cardiovascular risk.

Yoga is a part of the spiritual and physical habits of millions of people throughout the world. As yoga becomes a more widely practised form of exercise, study into the subject is growing. It is a versatile kind of exercise that can improve overall health and cardiovascular fitness. While there are many similarities between stretching exercises and the physical practises of yoga, there are also notable differences.

“The aim of this pilot study was to determine whether the addition of yoga to a regular exercise training regimen reduces cardiovascular risk,” explained lead investigator Paul Poirier, MD, PhD, Quebec Heart and Lung Institute – Laval University, and Faculty of Pharmacy, Laval University, Quebec, Canada.

“While there is some evidence that yoga interventions and exercise have equal and/or superior cardiovascular outcomes, there is considerable variability in yoga types, components, frequency, session length, duration, and intensity. We sought to apply a rigorous scientific approach to identify cardiovascular risk factors for which yoga is beneficial for at-risk patients and ways it could be applied in a healthcare setting such as a primary prevention program.”

For an exercise training programme, researchers included 60 people with metabolic syndrome and previously confirmed high blood pressure. Participants were split into two groups for the duration of the three-month intervention programme, and each group engaged in 15 minutes of organised yoga or stretching in addition to five sessions of 30 minutes of aerobic activity.

The Framingham and Reynolds Risk Scores, anthropometry, high-sensitivity C-reactive protein (hs-CRP), glucose, and cholesterol levels, as well as blood pressure, were all assessed. Age, sex, smoking rates, body mass index (BMI), resting systolic and diastolic blood pressure, resting heart rate, and pulse pressure did not differ across groups at the beginning of the study.

Both groups’ resting systolic and diastolic blood pressure, mean arterial blood pressure, and heart rates decreased after 3 months. Stretching only decreased systolic blood pressure by 4 mmHg, whereas yoga reduced it by 10 mmHg. Additionally, the yoga method decreased the 10-year cardiovascular risk score and resting heart rate.

Yoga has been demonstrated to help hypertension patients, although the precise mechanism by which it does so is still unclear. This pilot randomised trial demonstrates that stretching alone cannot account for all of its positive effects.

“This study provides evidence for an additional non-pharmacologic therapy option for cardiovascular risk reduction and blood pressure control in patients with high blood pressure, in the setting of a primary prevention exercise program,” noted Dr Poirier.

“As observed in several studies, we recommend that patients try to find exercise and stress relief for the management of hypertension and cardiovascular disease in whatever form they find most appealing. Our study shows that structured yoga practices can be a healthier addition to aerobic exercise than simply muscle stretching.”